Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market
According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable.
In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potential results in reducing PTSD symptoms by allowing clients to address their trauma in a secure and controlled environment. Limbix and Psious, for example, are developing VRET platforms to treat PTSD and other mental health problems.
Competitive Landscape
Key players in the post-traumatic stress disorder (PTSD) treatment market are: Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova
Browse Detail Summary@ https://www.futuremarketinsights.com/reports/post-traumatic-stress-disorder-treatment-market
Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey
By Drug Class:
- Antidepressants
- Anti-anxiety Drugs
- Antipsychotics
- Other Drug Classes
By Distribution Channel:
- Retail Pharmacies
- Online Pharmacies
Comments
Post a Comment